Volitionrx awarded $1.5 million in non-dilutive funding

Henderson, nev. , aug. 3, 2022 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from namur invest capital risk in belgium.

VNRX Ratings Summary

VNRX Quant Ranking